OptimizeRx Corp OPRX.OQ OPRX.O is expected to show a rise in quarterly revenue when it reports results on November 13 for the period ending September 30 2024
The Waltham Massachusetts-based company is expected to report a 53.1% increase in revenue to $24.997 million from $16.33 million a year ago, according to the mean estimate from 7 analysts, based on LSEG data.
LSEG's mean analyst estimate for OptimizeRx Corp is for earnings of 6 cents per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for OptimizeRx Corp is $15.00, above its last closing price of $6.06.
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Jun. 30 2024 | -0.06 | -0.06 | 0.02 | Beat | 131.3 |
Jan. 1 2024 | -0.12 | -0.13 | -0.11 | Beat | 13.7 |
Dec. 31 2023 | 0.33 | 0.32 | 0.26 | Missed | -19.5 |
Sep. 30 2023 | 0.03 | 0.03 | 0.09 | Beat | 260 |
Jun. 30 2023 | -0.02 | -0.02 | -0.01 | Beat | 53.3 |
Mar. 31 2023 | -0.08 | -0.08 | -0.09 | Missed | -12.5 |
Dec. 31 2022 | 0.25 | 0.24 | 0.25 | Beat | 3.6 |
Sep. 30 2022 | 0.03 | 0.04 | 0.07 | Beat | 90.7 |
This summary was machine generated November 12 at 03:47 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。